Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDRT + Durvalumab + EP in 1L ES-SCLC
NCT05092412Phase 2Active, not recruiting
- Start
- Mar 2022
- Primary completion
- Feb 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in small cell lung cancer (SCLC). Primary endpoint: Progression-Free Survival up to 2 years. Started Mar 2022; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05092412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05092412.